Abstract
Twenty patients with perennial nasal allergy were treated with Linovin nebulizer or nasal spray, histamine-carried human gamma globulin.
1. In the group treated with Linovin nebulizer (1/3v) twice a week for 4 weeks, the clinical effect was good in 3 cases (42.9%).
2. In the group treated with Linovin nasal spray (1 or 2v/w) using the device for nose drop, the clinical effect was excellent in 8 cases (61.5%) and good in 5 cases (38.5%).
3. Symptomatic improvement was apparent within two weeks of nasal spray therapy, earlier than in those treated with Linovin nebulizer.
4. No side effects were observed in any patients.
Linovin nasal spray using the device for nose drops is useful for patients suffering from allergic rhinitis.
